ARID1A mutation sensitizes most ovarian clear cell carcinomas to BET inhibitors
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
ARID1A mutation sensitizes most ovarian clear cell carcinomas to BET inhibitors
Authors
Keywords
-
Journal
ONCOGENE
Volume -, Issue -, Pages -
Publisher
Springer Nature
Online
2018-05-11
DOI
10.1038/s41388-018-0300-6
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Distinct Roles of Brd2 and Brd4 in Potentiating the Transcriptional Program for Th17 Cell Differentiation
- (2017) Ka Lung Cheung et al. MOLECULAR CELL
- ARID1A-mutated ovarian cancers depend on HDAC6 activity
- (2017) Benjamin G. Bitler et al. NATURE CELL BIOLOGY
- Functional Genomic Landscape of Human Breast Cancer Drivers, Vulnerabilities, and Resistance
- (2016) Richard Marcotte et al. CELL
- Synthetic Lethal Targeting of ARID1A -Mutant Ovarian Clear Cell Tumors with Dasatinib
- (2016) Rowan E. Miller et al. MOLECULAR CANCER THERAPEUTICS
- Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers
- (2015) Benjamin G Bitler et al. NATURE MEDICINE
- Biobanking of patient and patient-derived xenograft ovarian tumour tissue: efficient preservation with low and high fetal calf serum based methods
- (2015) Nicolette G. Alkema et al. Scientific Reports
- PTPN11 Is a Central Node in Intrinsic and Acquired Resistance to Targeted Cancer Drugs
- (2015) Anirudh Prahallad et al. Cell Reports
- BET Protein Inhibitor JQ1 Attenuates Myc-Amplified MCC Tumor Growth In Vivo
- (2014) Q. Shao et al. CANCER RESEARCH
- MTH1 inhibition eradicates cancer by preventing sanitation of the dNTP pool
- (2014) Helge Gad et al. NATURE
- ARID1B is a specific vulnerability in ARID1A-mutant cancers
- (2014) Katherine C Helming et al. NATURE MEDICINE
- Targeting bromodomains: epigenetic readers of lysine acetylation
- (2014) Panagis Filippakopoulos et al. NATURE REVIEWS DRUG DISCOVERY
- Intrinsic Resistance to MEK Inhibition in KRAS Mutant Lung and Colon Cancer through Transcriptional Induction of ERBB3
- (2014) Chong Sun et al. Cell Reports
- ARID1B, a member of the human SWI/SNF chromatin remodeling complex, exhibits tumour-suppressor activities in pancreatic cancer cell lines
- (2013) M Khursheed et al. BRITISH JOURNAL OF CANCER
- New insights into ovarian cancer pathology
- (2012) J. Prat ANNALS OF ONCOLOGY
- Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
- (2012) Anirudh Prahallad et al. NATURE
- Role of histological type on surgical outcome and survival following radical primary tumour debulking of epithelial ovarian, fallopian tube and peritoneal cancers
- (2011) E-I Braicu et al. BRITISH JOURNAL OF CANCER
- BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc
- (2011) Jake E. Delmore et al. CELL
- A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations
- (2010) Sreenath V. Sharma et al. CELL
- Selective inhibition of BET bromodomains
- (2010) Panagis Filippakopoulos et al. NATURE
- ARID1AMutations in Endometriosis-Associated Ovarian Carcinomas
- (2010) Kimberly C. Wiegand et al. NEW ENGLAND JOURNAL OF MEDICINE
- Frequent Mutations of Chromatin Remodeling Gene ARID1A in Ovarian Clear Cell Carcinoma
- (2010) Siân Jones et al. SCIENCE
- Differential expression analysis for sequence count data
- (2010) Simon Anders et al. GENOME BIOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started